×
ASCO20 Virtual Scientific Program Showcases the Latest Advances in Melanoma Research
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200224/full/
ASCO Daily News;

Jun 24th, 2020 - The ASCO20 Virtual Scientific Program featured a range of studies showcasing the latest advances and clinical breakthroughs in melanoma research.

Lack of evidence to support large-panel genomic testing in treatment selection for malignant melanoma.
https://meetinglibrary.asco.org/record/189194
Maya Dimitrova, MD

May 28th, 2020 - Background: Genomic profiling informs clinical decision-making for malignant melanoma (MM) as specific tumor mutations can be treated with targeted therapy (TT). However, given the range of different panel sizes available and increasing use of immune checkpoint inhibitors (ICI), the clinical significance of upfront, large-panel genomic profiling in MM remains undetermined. Herein, we investigat...

The use of PET/CT to detect early recurrence after resection of high-risk stage III melanoma, prior to the start of adjuvant therapy and during follow-up.
https://meetinglibrary.asco.org/record/189095
Bernies Van Der Hiel, MD

May 28th, 2020 - Background: To date, international consensus concerning the use of PET/CT as a surveillance tool in the follow-up of high-risk melanoma patients after complete resection of disease is lacking. Moreover, with the rise of adjuvant therapy it seems appropriate to investigate the role of this imaging modality to exclude newly developed metastases after resection and prior to starting treatment. The...

Bioinformatic profiling of tumor immunity from patient biopsies to predict survival and response to immunotherapy.
https://meetinglibrary.asco.org/record/189277
Yamil Damian Mahmoud

May 28th, 2020 - Background: Immunotherapies have revolutionized cancer treatment, but responses are not universal and patients who initially respond to therapy develop resistance. The accurate quantification of tumor-infiltrating immune cells holds the promise to reveal the role of the immune system in human cancers and its involvement in tumor escape mechanisms and response to therapy. We present MIXTURE, a n...

Comparison of baseline patient characteristics in immunotherapy versus targeted therapy trials for advanced melanoma.
https://meetinglibrary.asco.org/record/188748
Shivani Handa, MD

May 28th, 2020 - Background: Immune checkpoint inhibitors (ICI) or BRAF/MEK targeted therapy are both FDA approved first line options for BRAF mutant advanced melanoma. However, the optimal sequencing of these approaches and the profile of patients who benefit the most from one treatment over the other is suboptimally defined. Methods: We compared the baseline characteristics of the participants enrolled in the...

Correlation of nivolumab 480 mg Q4W with better survival than other nivolumab monotherapy schedule in metastatic melanoma patients.
https://meetinglibrary.asco.org/record/188716
Ester Simeone

May 28th, 2020 - Background: Nivolumab (nivo) 480 mg (Q4W) flat dose has already been assessed for safety compared to other drug dose regimens in clinical trials [1]. However, few data about melanoma patients treated in real life are available. The aim of our study was to evaluate safety and efficacy in metastatic melanoma pts treated with different schedules of nivo in clinical practice. Methods: We analyzed d...

Single-institution outcomes with less than two-year anti-PD-1 antibody therapy in metastatic melanoma.
https://meetinglibrary.asco.org/record/188750
Tsering G. Lama Tamang, MD

May 28th, 2020 - Background: Optimal duration of anti-PD-1 antibody therapy remains undefined. Currently, treatment is given up to two years in metastatic melanoma based on clinical trials. However, recent observations suggest that anti-PD-1 antibodies may work as well if given for shorter time periods. To better understand duration of anti-PD-1 antibody treatment, we reviewed outcomes for patients who disconti...

Unknown primary tumor high-risk melanoma as a unique patient population with distinct prognosis in the adjuvant setting: An ECOG-ACRIN E1609 study analysis.
https://meetinglibrary.asco.org/record/189137
Ahmad A. Tarhini, MD, PhD

May 28th, 2020 - Background: E1609 enrolled 1670 adult patients (pts) with resected AJCC7 stages IIIB, IIIC, M1a, M1b melanoma and compared adjuvant ipilimumab at 3 or 10 mg/kg (ipi3 and ipi10) to high dose interferon-alfa (HDI). With over 5 years of follow up, the risk of relapse and death by primary tumor status and by stage group is expected to inform the design of future adjuvant trials and ultimately, clin...

Predictors of extensive subclinical spread in squamous cell carcinoma.
https://meetinglibrary.asco.org/record/189176
Anna Eversman, BS

May 28th, 2020 - Background: Extensive spread of squamous cell carcinoma (SCC) is often clinically imperceptible but has a profound impact on risk of recurrence and metastasis. Accurate identification of high-risk SCC enables educated choices in treatment modality and appropriate referrals for Mohs micrographic surgery (MMS). Methods: We conducted a retrospective cohort study of 1,019 patients with SCC removal ...

Adjuvant therapy in non-metastatic melanoma result from a Brazilian cohort.
https://meetinglibrary.asco.org/record/187711
Sinara Figueiredo Silva

May 28th, 2020 - Background: The PD-1–blocking antibodies, combination of target therapy and anti-CTLA4 have shown a favorable safety profile with better efficacy than high-dose interferon in the adjuvant setting. However, in Brazil only a minority of patients in private institutions have access to new therapies in adjuvants. Here, we describe the evolution of patients with non metastatic melanoma who received ...

Toxicities with combination BRAF and MEK inhibition in resected stage III melanoma.
https://meetinglibrary.asco.org/record/189162
Govind Warrier, MD, MPH

May 28th, 2020 - Background: Patients with stage III melanoma are at high risk for recurrence after resection of the primary lesion. The Combi-AD study showed adjuvant therapy with BRAF inhibitor, dabrafenib (D), and MEK inhibitor, trametinib (T), in patients with resected stage III BRAF mutant melanoma offers recurrence free survival benefit at 3 and 4 years compared to placebo. In this study, adverse events l...

Clinical experience with the targeted therapy in melanoma patients with brain metastases.
https://meetinglibrary.asco.org/record/188523
Natalia V. Zhukova

May 28th, 2020 - Background: According to the clinical studies, the frequency of melanoma brains metastasis reaches 43%, and according to autopsy data, this percentage is even higher - up to 75%. New drugs in clinical practice has significantly improved the prognosis of the metastatic melanoma, however, patients with metastases in the brain are often excluded from large clinical studies, which limits the eviden...

Performance of a prognostic 31-gene expression profile test in patients with node-negative cutaneous melanoma.
https://meetinglibrary.asco.org/record/189181
Pedram Gerami, MD

May 28th, 2020 - Background: The National Comprehensive Cancer Network guidelines recommend considering sentinel lymph node biopsy (SLNB) for cutaneous melanoma (CM) patients with a 5-10% risk of SLN positivity and offering it to those with > 10% risk. However, SLNB limitations include identification of only 1/3 of patients who end up with distant metastasis and a regional metastasis false negative rate ranging...

Association of prior interferon-alpha treatment with the efficacy of adjuvant pembrolizumab in resected melanoma.
https://meetinglibrary.asco.org/record/188499
Gu Jin

May 28th, 2020 - Background: Adjuvant pembrolizumab or interferon-alpha has been found to prolong recurrence-free survival as adjuvant therapy for resected melanoma. Several studies have shown that interferon-alpha could modulate immune responses to melanoma. In this study, we provided clear evidence that prior treatment with interferon-alpha significantly enhanced the efficacy of adjuvant pembrolizumab for res...

Interim results of prospective pilot phase II trial of concurrent anti-PD-1 and stereotactic radiosurgery (SRS) for melanoma and NSCLC patients with brain metastases (NCT02858869).
https://meetinglibrary.asco.org/record/189191
Mohammad Khurram Khan, MD, PhD

May 28th, 2020 - Background: The safety and efficacy of concurrent radiotherapy (SRS) and single agent (anti-PD-1) checkpoint inhibitor have not been established. We report the first results of an interim analysis from a prospective pilot phase II trial of cocurrent anti-PD-1 (pembrolizumab) and SRS for brain metastases Methods: Food and Drug Administration (FDA) and Institutional Review Board (IRB) approval we...

Local hormonal status of tumor and adjacent tissues in patients with melanoma depending on their gender.
https://meetinglibrary.asco.org/record/188856
Valeria A. Bandovkina

May 28th, 2020 - Background: Gender is an important independent prognostic factor for cutaneous melanoma incidence, and survival in women is better. The purpose of the study was to determine the content of sex steroids and prolactin in tumor, perifocal and resection line tissues in male and female patients with melanoma. Methods: The study included 13 men and 22 women with cutaneous melanoma (M) pT1-2N0M0. Leve...

The relationship between tumor-infiltrating lymphocytes, PD-L1 expression, and clinical outcomes of Asian melanoma patients treated with anti-PD-1 antibody.
https://meetinglibrary.asco.org/record/188533
Soo Jung Lee, MD. Ph.D.

May 28th, 2020 - Background: Clinical feature of Asian melanoma patients are distinct from those of Western patients. Acral and mucosal melanomas, which are common in Asian populations, predominantly occur in sun-protected areas. Immune-checkpoint inhibitors are standard treatment for inoperable melanoma, however, they are less effective against acral and mucosal melanomas. The aim of our study is to investigat...

Role of AXL in metastatic melanoma and impact of TP-0903 as a novel therapeutic option for melanoma brain metastasis.
https://meetinglibrary.asco.org/record/189195
Eemon Tizpa, BA, MS

May 28th, 2020 - Background: Melanoma brain metastases (MBM) are common with a median overall survival of 4-5 months. Although immunotherapies have improved clinical outcomes and have doubled overall survival in MBM, there is a high incidence rate of relapse caused by drug resistance. AXL, a receptor tyrosine kinase (RTK), is associated with drug resistance and metastasis in many cancers. The activation of AXL ...

Efficacy and safety of apatinib in patients with recurrent or refractory melanoma.
https://meetinglibrary.asco.org/record/188804
Zibing Wang

May 28th, 2020 - Background: The prognosis of patients with metastatic malignant melanoma is very poor, a fact that is partly due to its high resistance to conventional chemotherapies. The objectives of this phase II trial were to assess the activity and tolerability of apatinib, an oral small molecule anti-angiogenesis inhibitor, in patients with recurrent advanced melanoma. Methods: This was a single arm, sin...

Patterns of hepato-pulmonary metastasis and their impact on clinical outcomes in uveal melanoma.
https://meetinglibrary.asco.org/record/189106
Asad Javed, MBBS

May 28th, 2020 - Background: Metastatic Uveal Melanoma (MUM) is a rare tumor with poor prognosis following development of liver metastasis. We hypothesized that patterns of metastasis in Uveal Melanoma correlate with clinical outcomes. Methods: We retrospectively reviewed patients with MUM at Mayo Clinic, Rochester from January 1999 to August 2019. Patients were stratified into two groups based on the pattern o...